Leading Australian health accelerator announces key commercial outcomes at global HLTH conference
30 October 2019 ANDHealth, Australia’s leading health technology accelerator which focuses solely on supporting the commercialisation of disruptive and digital health technologies, today announced the two year commercial growth outcomes of its first 10 ANDHealth+ cohort companies. Since…
Marketing email using BioMelbourne Network name – please ignore
1 November 2019 Some BioMelbourne Network members have received an email like this one using the BioMelbourne Network name. If you receive this or something similar, please ignore it. This has nothing to do with BioMelbourne Network and…
4Dx Celebrates Confirmatory Clinical Trial Success of its XV Lung Imaging Technology
29 October 2019 Melbourne, Australia, 29 October 2019 Australian medical technology company 4Dx Limited has attained excellent results in a major clinical trial of its patented four-dimensional lung imaging technology. The confirmatory clinical trial showed that XV Technology™…
Leading health executive appointed new Chair of ANDHealth
17 October 2019 One of Australia’s most experienced health sector executives, Gavin Fox-Smith, has been appointed the new Chair of leading digital health accelerator, ANDHealth, after Dr Anna Lavelle announced her retirement as Chair of the Board. Dr…
David Haylock, PhD Appointed as Chief Executive Officer
30 October 2019 Melbourne, Australia: VivaZome Therapeutics Pty Ltd (“VivaZome”) is pleased to announce that Dr David Haylock has been appointed as Chief Executive Officer (CEO), effective as of 01 November, 2019. Dr Haylock has collaborated with VivaZome…
Victorian healthtech startups go-to-market in the USA
30 October 2019 Five Victorian medical device startups are better placed to take on the world after visiting Minnesota for the final Masterclass of BioMelbourne Network’s 2019 Healthtech Reimbursement program. Go-To-Market in the USA was a three-day experiential…
Takeda Pharmaceuticals and BioCurate announce collaboration to accelerate innovative early stage discoveries of new therapeutics and drugs
30 October 2019 Melbourne – BioCurate, a joint venture between Monash University and The University of Melbourne with support from the Victorian State Government, has signed an agreement with Takeda Pharmaceutical Company Limited (Takeda) to share commercial and…
AD-214 safe in non-human primates, bulk manufacturing complete
29 October 2019 MELBOURNE Australia: AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, is pleased to announce the completion of its non-human primate study program necessary to enable the phase I…
Former Cochlear CEO Dr. Chris Roberts AO joins Atmo Biosciences Board
29 October 2019 Melbourne, Australia Former Cochlear Chief Executive Officer Dr. Chris Roberts AO has been appointed as a Non-Executive Director to the Board of Atmo Biosciences, a digital health business commercializing a world-first ingestible gas-sensing capsule that…
What’s Holding Up Digital Pathology?
28 October 2019 By Richard Lash MD, and Caroline Popper MD For centuries, the basics of pathologic examination of human tissue under a microscope has essentially remained unchanged. The excitement about Digital Pathology (creating digital images of the…
Ransomware – A first-hand account
28 October 2019 By Dr Irving Hofman RYUK is a sophisticated cryptoware with ransom requests of the order of half a million US dollars. The healthcare sector in Australia has become a specific target. Recently, the Exigence cybersecurity…
Dimerix awarded second Innovation Connections Grant
23 October 2019 MELBOURNE, Australia: Dimerix Limited (ASX: DXB), a clinical-stage drug development company, announced today that it has been awarded a second Innovation Connections Grant, which is supported by the Australian Government’s Department of Industry, Innovation and…
